1st Nov 2018 13:41
LONDON (Alliance News) - NetScientific PLC said Thursday that its 66%-owned US-based portfolio company, Vortex BioSciences, has entered into a global manufacturing agreement with Stratec Consumables GmbH to produce a customised chip, a crucial component of Vortex's automated liquid biopsy medical platform.
Stratec will also assist Vortex with scale-up to commercialisation with a view to increasing the product's prominence in the clinical space as a diagnostic and monitoring tool.
"Partnering with Stratec to manufacture the VTX-1 microfluidic chip will create a reproducible process that will allow Vortex's technology to enter the market and readily address demand as it surges. We look forward to the results of this collaboration and foresee Vortex playing a crucial role in establishing CTCs as part of the standard of care in oncology treatment," NetScientific Chief Executive & Vortex Chairman Francois Martelet said.
Shares in the healthcare technology commercialisation company were down 3.0% at 28.12 pence each.
Related Shares:
Netscientific